Hair Loss

Clin Ther. 2009;31:2242

Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets. Chen L, et al

BFinasteride, an inhibitor of the steroid 5alpha-reductase, has been approved for the treatment of benign prostatic hyperplasia and androgenetic alopecia or male pattern hair loss. A 5-mg formulation of finasteride was recently developed. snip..). No adverse events were reported by the volunteers or found in clinical laboratory testing during the study. Conclusions: In this single-dose study, based on the rate and extent of absorption, the ODT (ie, test) and standard tablet (ie, reference) formulations of finasteride met the regulatory criteria for bioequivalence in these fasting healthy adult male Han Chinese volunteers. However, a significant difference was found for T(max) between the test and reference formulations. Both formulations were well tolerated.